Stay on: Osiris Therapeutics (NASDAQ:OSIR), Sequans Communications S.A. (NYSE:SQNS), Clifton Bancorp Inc. (NASDAQ:CSBK), Kona Grill Inc. (NASDAQ:KONA), Gilead Sciences Inc. (NASDAQ:GILD)

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced that it will report its financial results for fourth quarter and full year ended December 31, 2014, on Thursday, March 5, 2015. On Tuesday shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) closed at $16.15. Company’s sales growth for last 5 years was 19.40%.

On February 11, Sequans Communications S.A. (NYSE:SQNS) announced financial results for the fourth quarter and full year ended December 31, 2014. Revenue of $6.6 million increased 2% compared to the third quarter of 2014, with slightly higher product sales partially offset by lower other revenue. Sequans Communications S.A. (NYSE:SQNS) in last trading activity advanced 8.94% to close at $1.95. Company weekly performance is 50.00% while its quarterly performance stands at 36.36%. Sequans Communications S.A. (NYSE:SQNS) is -42.65% away from its 52 week high.

On February 4, Clifton Bancorp Inc. (NASDAQ:CSBK) said fiscal third-quarter net income rose to $1.94 million, or 8 cents a share, from $1.76 million, or 7 cents, from the same period a year ago. On last trading day Clifton Bancorp Inc. (NASDAQ:CSBK) decreased -0.59% to close at $13.38. Its volatility for the week is 1.44% while volatility for the month is 1.54%. CSBK’s sales growth for past 5 years was -5.40% and its EPS growth for past 5 years was 5.40%. Clifton Bancorp Inc. (NASDAQ:CSBK) monthly performance is 0.98%.

Kona Grill, Inc. (Nasdaq:KONA), will hold a conference call on Tuesday, February 24, 2015 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2015. The Company will report its financial results in a press release prior to the call. Kona Grill Inc. (NASDAQ:KONA) has 7.80% insider ownership while its institutional ownership stands at 67.90%. In last trading activity company’s stock closed at $24.13.

Natco Pharma Ltd. has urged the high court to reject Gilead Sciences Inc. (NASDAQ:GILD)’s bid to review a decision on double-patenting, saying the Federal Circuit’s ruling that a patent was obvious in light of a patent that was filed after, but expired before, the first patent was nothing extraordinary. On Tuesday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $103.84. Company’s sales growth for last 5 years was 28.80% and EPS growth for next 5 years is recorded as 25.20%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*